Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Small Cell Lung Carcinoma 11Neoplasms 6Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Recurrence 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Melanoma 1Head and Neck Neoplasms 1Glioblastoma 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 15avelumab 12Nivolumab 9atezolizumab 5Cyclophosphamide 5fludarabine 4Interleukin-2 4ALT-803 4durvalumab 3cemiplimab 3aldesleukin 3Ipilimumab 3domatinostat 2budigalimab 2Paclitaxel 2Docetaxel 2Bevacizumab 2zimberelimab 1venetoclax 1talimogene laherparepvec 1rovalpituzumab tesirine 1regorafenib 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1lorvotuzumab mertansine 1glucopyranosyl lipid-A 1epacadostat 1efineptakin alfa 1daromun 1bempegaldesleukin 1aflibercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Merkel Cell × rovalpituzumab tesirine × Clear all
NCT03000257 2022-04-14

A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors

AbbVie

Phase 1 Completed
182 enrolled
BreastDermatologicGastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Mesothelioma, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡